Company news
Protara Therapeutics, Inc. (NASDAQ:TARA) news
Protara Therapeutics, Inc. news releases on 6ix. Latest, Feb 2, 2021: Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
Press releases — page 3
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
February 1, 2021
Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
December 6, 2020
Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
November 11, 2020
Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
September 21, 2020
Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
September 20, 2020
Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
September 7, 2020
Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview
August 2, 2020
Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations
July 27, 2020
Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
July 23, 2020
Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
May 25, 2020
Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview
May 12, 2020
ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics
May 10, 2020
ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 1, 2020
ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer
February 10, 2020